RJA
BHVN

Raymond James & Associates’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

Raymond James & Associates’s Portfolio BHVN Stock Details BHVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-12,070
Closed -$1.82M – 4156
2022
Q3 		$1.82M Sell
12,070
-24,559
-67% -$3.64M ﹤0.01% 2031
2022
Q2 		$5.34M Sell
36,629
-2,238
-6% -$286K 0.01% 1363
2022
Q1 		$4.61M Buy
38,867
+2,167
+6% +$270K ﹤0.01% 1567
2021
Q4 		$5.06M Buy
36,700
+16,995
+86% +$2.16M ﹤0.01% 1547
2021
Q3 		$2.74M Sell
19,705
-112
-0.6% -$14K ﹤0.01% 1881
2021
Q2 		$1.92M Buy
19,817
+1,158
+6% +$94K ﹤0.01% 2128
2021
Q1 		$1.27M Buy
18,659
+6,907
+59% +$559K ﹤0.01% 2334
2020
Q4 		$1.01M Sell
11,752
-364
-3% -$30.8K ﹤0.01% 2342
2020
Q3 		$788K Buy
12,116
+884
+8% +$57.9K ﹤0.01% 2322
2020
Q2 		$821K Sell
11,232
-77
-0.7% -$4.1K ﹤0.01% 2289
2020
Q1 		$385K Buy
11,309
+1,918
+20% +$87.7K ﹤0.01% 2605
2019
Q4 		$511K Sell
9,391
-4,273
-31% -$212K ﹤0.01% 2725
2019
Q3 		$570K Sell
13,664
-199
-1% -$8.41K ﹤0.01% 2559
2019
Q2 		$607K Sell
13,863
-3,396
-20% -$191K ﹤0.01% 2534
2019
Q1 		$888K Buy
17,259
+148
+0.9% +$6.39K ﹤0.01% 2276
2018
Q4 		$633K Sell
17,111
-239
-1% -$8.62K ﹤0.01% 2386
2018
Q3 		$651K Sell
17,350
-222
-1% -$8.17K ﹤0.01% 2528
2018
Q2 		$694K Sell
17,572
-32
-0.2% -$1.01K ﹤0.01% 2453
2018
Q1 		$453K Buy
17,604
+1,095
+7% +$32.7K ﹤0.01% 2626
2017
Q4 		$445K Buy
16,509
+758
+5% +$20.9K ﹤0.01% 2606
2017
Q3 		$589K Buy
15,751
+41
+0.3% +$1.24K ﹤0.01% 2386
2017
Q2 		$393K Buy
+15,710
New +$362K ﹤0.01% 2561

Other funds holding BHVN

LIP
Liontrust Investment Partners London, United Kingdom $5.86B AUM 23.75% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
MSCM
McElhenny Sheffield Capital Management Dallas, Texas $404M AUM 19.8% 1-Year Est. Return

Raymond James & Associates's BHVN Position: Q4 2022 in Review

Raymond James & Associates sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q4 2022, closing a stake of 12,070 shares — an estimated $1.82M sold.

Raymond James & Associates first reported a position in BHVN in Q2 2017 and held it in 22 quarters. The position peaked at $5.34M in Q2 2022. 7 funds tracked by Wall St. Rank hold BHVN as of Q4 2022.

  • Raymond James & Associates reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q4 2022 after selling out during the quarter.
  • Raymond James & Associates sold 12,070 Biohaven Pharmaceutical Holding Company Ltd. shares in Q4 2022, an estimated $1.82M.
  • Raymond James & Associates first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q2 2017 and held it in 22 quarters.
  • Raymond James & Associates's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $5.34M in Q2 2022.
  • 7 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q4 2022.

Based on Raymond James & Associates's 13F filing for Q4 2022, filed 8 Feb 2023.